跳至主要内容
临床试验/NL-OMON49970
NL-OMON49970尚未招募不适用

Improving the safety of fluoropyrimidine-based chemotherapy by combined DPYD genotype-guided and DPD phenotype-guided dose individualisation: The Alpe2U study - Improving the safety of fluoropyrimidine-based chemotherapy

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 1,440 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,440

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Pathologically confirmed malignancy for which treatment with a
  • fluoropyrimidine is considered to be in the patient*s best interest
  • 2. Patient need to be of Western descent
  • 3. Age >= 18
  • 4. Able and willing to give written informed consent
  • 5. WHO performance status of 0, 1 or 2
  • 6. Able and willing to undergo extra blood sampling for study related analysis
  • 7. Adequate baseline patient characteristics (complete blood count, hepatic
  • function which involves serum bilirubin, AST, ALT, and renal function)

排除标准

  • 1. Prior treatment with fluoropyrimidines
  • 2. Patients with known substance abuse, psychotic disorders, and/or other
  • diseases expected to interfere with study or the patient*s safety
  • 3. Patients treated with the combination of a fluoropyrimidine and irinotecan

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验